Cargando…

Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age

BACKGROUND: Dimethyl fumarate (DMF) is licensed for treatment of relapsing–remitting multiple sclerosis (RRMS). DMF can induce lymphopenia, which is assumed to increase the risk for opportunistic infections like progressive multifocal leukoencephalopathy. Our goal for this work was to estimate the f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Briner, Myriam, Bagnoud, Maud, Miclea, Andrei, Friedli, Christoph, Diem, Lara, Chan, Andrew, Hoepner, Robert, Salmen, Anke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506915/ https://www.ncbi.nlm.nih.gov/pubmed/31105768 http://dx.doi.org/10.1177/1756286419843450

Ejemplares similares

Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study
por: Diem, Lara, et al.
Publicado: (2020)

Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course
por: Zoehner, Greta, et al.
Publicado: (2019)

An algorithm using clinical data to predict the optimal individual glucocorticoid dosage to treat multiple sclerosis relapses
por: Gili-Kovács, Judit, et al.
Publicado: (2021)

Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)

Vaccine Hesitancy in Patients With Multiple Sclerosis: Preparing for the SARS-CoV-2 Vaccination Challenge
por: Diem, Lara, et al.
Publicado: (2021)

c-Jun N-Terminal Kinase as a Therapeutic Target in Experimental Autoimmune Encephalomyelitis
por: Bagnoud, Maud, et al.
Publicado: (2020)

Evaluation of diagnostic criteria and red flags of myelin oligodendrocyte glycoprotein encephalomyelitis in a clinical routine cohort
por: Veselaj, Krenar, et al.
Publicado: (2020)

Age‐dependent variation of female preponderance across different phenotypes of multiple sclerosis: A retrospective cross‐sectional study
por: Miclea, Andrei, et al.
Publicado: (2018)

A Brief Review of the Effects of Vitamin D on Multiple Sclerosis
por: Miclea, Andrei, et al.
Publicado: (2020)

Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance
por: Longbrake, Erin E, et al.
Publicado: (2015)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
por: Ghadiri, Mahtab, et al.
Publicado: (2017)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

Predicting conversion to multiple sclerosis in patients with radiologically isolated syndrome: a retrospective study
por: Chaloulos-Iakovidis, Panagiotis, et al.
Publicado: (2021)

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
por: Sangurdekar, Dipen, et al.
Publicado: (2019)

Multiple sclerosis as a model to investigate SARS‐CoV‐2 effect on brain atrophy
por: Rebsamen, Michael, et al.
Publicado: (2022)

CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient
por: Kogel, Ann-Kathrin, et al.
Publicado: (2021)

Is COVID‐19 severity associated with reduction in T lymphocytes in anti‐CD20‐treated people with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?
por: Hoepner, Robert, et al.
Publicado: (2022)

Fatigue in Post-COVID-19 Syndrome: Clinical Phenomenology, Comorbidities and Association With Initial Course of COVID-19
por: Diem, Lara, et al.
Publicado: (2022)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

In Vivo and In Vitro Evidence for an Interplay between the Glucocorticoid Receptor and the Vitamin D Receptor Signaling
por: Bagnoud, Maud, et al.
Publicado: (2023)

Application of the “risk of ambulatory disability” (RoAD) score in a “real‐world” single‐center multiple sclerosis cohort
por: Pistor, Maximilian, et al.
Publicado: (2022)

Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies
por: Friedli, Christoph, et al.
Publicado: (2021)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
por: Hammer, Helly, et al.
Publicado: (2022)

Multidimensional phenotyping of the post‐COVID‐19 syndrome: A Swiss survey study
por: Diem, Lara, et al.
Publicado: (2022)

Prediction of conversion to multiple sclerosis using the 2017 McDonald and 2016 MAGNIMS criteria in patients with clinically isolated syndrome: a retrospective single-centre study
por: Miclea, Andrei, et al.
Publicado: (2019)

Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations
por: Remlinger, Jana, et al.
Publicado: (2023)

Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis
por: Hoepner, Robert, et al.
Publicado: (2019)

Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activity
por: Miclea, Andrei, et al.
Publicado: (2017)

Fumaric acid ester‐induced T‐cell lymphopenia in the real‐life treatment of psoriasis
por: Dickel, H., et al.
Publicado: (2019)

Dimethyl fumarate for ischemic stroke
por: Kunze, Reiner
Publicado: (2017)

Pathological cerebrospinal fluid protein concentration and albumin quotient at relapse predicts short-term disability progression in multiple sclerosis: a retrospective single center observational study
por: Diem, Lara, et al.
Publicado: (2020)

Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis
por: Kappos, L, et al.
Publicado: (2015)

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
por: Kowalec, Kaarina, et al.
Publicado: (2017)

Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate
por: Mathias, Amandine, et al.
Publicado: (2017)

Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016)

Effects of dimethyl fumarate on neuroprotection and immunomodulation
por: Albrecht, Philipp, et al.
Publicado: (2012)

Dimethyl fumarate mitigates optic neuritis
por: Zyla, Katarzyna, et al.
Publicado: (2019)

Dimethyl fumarate transfer into human milk
por: Ciplea, Andrea I., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2e4e91709tk6alc3iqqvp7llhb